


Improve Patient Outcomes Through Timely Care

CardioCare

Quality Optimization Platform



DELAYS IN CARE CAN HAVE STAGGERING CONSEQUENCES

Poor outcomes and high mortality are possible costs of delayed care for untreated patients with severe structural heart disease.

41%

severe mitral regurgitation patients hospitalized for heart failure at 1-year¹

20%

severe aortic stenosis patients developed heart failure at 1-year¹

\$1,199,062

heart failure hospitalization cost for untreated valvular heart disease^{1,2,3}



\$4,105,861

contribution margin loss for untreated valvular heart disease^{4,5}




\$5,304,924

average net income loss for untreated structural heart disease⁴

While heart programs may have different goals, one goal remains the same: to improve patient outcomes and provide timely, appropriate care to patients with structural heart disease.

THE CARDIOCARE PLATFORM CLOSSES GAPS IN THE PATIENT CARE PATHWAY⁶




6. Analysis represents aggregate median performance across 14 sites with baseline data after six months of using the CardioCare program. 7. Based on AHA/ACC guidelines. 8. Therapy plan encompasses medical management, palliative care or other medical procedures (surgical or transcatheter). Some patients diagnosed within 60 days of data collection may not have had enough time to receive a defined therapy plan.

INSIGHTS ENABLING PHYSICIANS TO IMPROVE GUIDELINE DIRECTED THERAPY

Patients Diagnosed with Severe Mitral Regurgitation^{9,10}

N=19 sites; October 2018 - May 2021




9. Analysis represents patients that had an echo between October 01, 2015 and May 07, 2021 and diagnosed with severe MR identified from proprietary natural language processing algorithms (NLP). Data collected on May 10, 2021. 10. Excludes patients 'Awaiting Follow-up'. 11. Includes 'Patient Refusals'. 12. Includes 'Not a Candidate' patients 13. Half of the expired patients were previously medically managed.

HELPING PHYSICIANS CLOSE TREATMENT GAPS USING ARTIFICIAL INTELLIGENCE



DIAGNOSTIC PRECISION

Predict the likelihood that a patient has been undiagnosed with severe AS



CARE PATHWAY OPTIMIZATION

Automatically identify and manage all SHD patients to ensure patients receive timely treatment



DISEASE PROGRESSION

Predict the likelihood that a moderate AS patient has progressed to severe disease

For more information, please visit egnitehealth.com/solutions

[@egnitehealth](https://twitter.com/egnitehealth) [in linkedin.com/company/egnite-health/](https://www.linkedin.com/company/egnite-health/)

* This product is not intended for use in the diagnosis, cure, mitigation, treatment or prevention of structural heart diseases.

References

1. Goel et al (JACC 2014) 2. Nagao et al (Circ. J., 2018). 3. S. Jackson (Circulation: Heart Failure, 2018 Dec 4. For the average hospital performing 20,000 echos annually, assumes blended transcatheter and surgical contribution margin for sAS & sMR patients at \$10,000 per procedure. 5. Includes potential revenue loss in pre-procedural diagnostic testing.

egnite, egnite Inc., the stylized logo, and CardioCare are trademarks of egnite, Inc.

All other trademarks are property of their respective owners.

©2021 egnite, Inc. All Rights Reserved.

egnite • 65 Enterprise, Suite 455 Aliso Viejo, CA 92656 • egnitehealth.com

PP-US-0034 v1.0

